Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$144.95 - $152.29 $14 Million - $14.7 Million
96,781 Added 50.66%
287,812 $43.5 Million
Q2 2022

Aug 12, 2022

SELL
$83.14 - $145.99 $41.1 Million - $72.1 Million
-493,803 Reduced 72.11%
191,031 $27.8 Million
Q1 2022

May 11, 2022

BUY
$110.08 - $142.92 $54.4 Million - $70.6 Million
494,275 Added 259.38%
684,834 $81.2 Million
Q4 2021

Feb 07, 2022

SELL
$99.73 - $148.48 $8.8 Million - $13.1 Million
-88,217 Reduced 31.64%
190,559 $26.3 Million
Q3 2021

Nov 10, 2021

BUY
$98.85 - $138.91 $9 Million - $12.6 Million
91,051 Added 48.5%
278,776 $38.7 Million
Q2 2021

Aug 05, 2021

BUY
$65.78 - $105.02 $111,562 - $178,113
1,696 Added 0.91%
187,725 $18.2 Million
Q1 2021

May 14, 2021

SELL
$64.07 - $91.75 $168,440 - $241,210
-2,629 Reduced 1.39%
186,029 $12.7 Million
Q4 2020

Feb 12, 2021

BUY
$65.07 - $98.24 $689,156 - $1.04 Million
10,591 Added 5.95%
188,658 $16.2 Million
Q3 2020

Nov 13, 2020

BUY
$59.04 - $77.95 $1.64 Million - $2.17 Million
27,811 Added 18.51%
178,067 $11.6 Million
Q2 2020

Aug 13, 2020

BUY
$29.01 - $74.23 $2.16 Million - $5.53 Million
74,466 Added 98.25%
150,256 $11 Million
Q1 2020

May 14, 2020

BUY
$27.51 - $57.29 $2.08 Million - $4.34 Million
75,790 New
75,790 $2.58 Million
Q1 2018

May 03, 2018

SELL
$22.49 - $34.56 $1.29 Million - $1.98 Million
-57,216 Closed
0 $0
Q4 2017

Feb 02, 2018

BUY
$20.44 - $35.56 $417,875 - $726,988
20,444 Added 55.6%
57,216 $1.54 Million
Q3 2017

Nov 01, 2017

BUY
$23.54 - $38.21 $865,612 - $1.41 Million
36,772
36,772 $1.38 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.18B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.